Zhihuang Hu

2.5k total citations
53 papers, 1.6k citations indexed

About

Zhihuang Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Zhihuang Hu has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Zhihuang Hu's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Zhihuang Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Zhihuang Hu collaborates with scholars based in China, United States and South Korea. Zhihuang Hu's co-authors include Wenfeng Fang, Yuanyuan Zhao, Yan Huang, Hongyun Zhao, Shaodong Hong, Yuxiang Ma, Yunpeng Yang, Li Zhang, Tao Qin and Cong Xue and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Zhihuang Hu

52 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhihuang Hu China 19 1.0k 601 514 387 205 53 1.6k
K. Syrigos Greece 23 1.1k 1.1× 638 1.1× 388 0.8× 288 0.7× 246 1.2× 73 1.9k
Pascal Wolter Belgium 26 1000 1.0× 790 1.3× 817 1.6× 308 0.8× 118 0.6× 86 2.0k
Alain Gelibter Italy 22 974 1.0× 574 1.0× 332 0.6× 333 0.9× 193 0.9× 100 1.4k
Óscar Juan Spain 22 1.4k 1.4× 1.3k 2.2× 526 1.0× 378 1.0× 196 1.0× 154 2.2k
Fumihiko Hirai Japan 26 1.1k 1.1× 979 1.6× 439 0.9× 181 0.5× 153 0.7× 103 1.8k
Lara Pijuán Spain 20 571 0.6× 680 1.1× 307 0.6× 311 0.8× 168 0.8× 74 1.3k
Morena Fasano Italy 20 680 0.7× 535 0.9× 605 1.2× 244 0.6× 139 0.7× 63 1.4k
Jesús García-Donás Spain 21 787 0.8× 557 0.9× 638 1.2× 430 1.1× 247 1.2× 116 1.7k
Nobuyuki Mizunuma Japan 23 1.5k 1.5× 530 0.9× 506 1.0× 367 0.9× 259 1.3× 133 2.0k
Mireia Margelí Vila Spain 20 784 0.8× 416 0.7× 440 0.9× 485 1.3× 174 0.8× 94 1.4k

Countries citing papers authored by Zhihuang Hu

Since Specialization
Citations

This map shows the geographic impact of Zhihuang Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhihuang Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhihuang Hu more than expected).

Fields of papers citing papers by Zhihuang Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhihuang Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhihuang Hu. The network helps show where Zhihuang Hu may publish in the future.

Co-authorship network of co-authors of Zhihuang Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhihuang Hu. A scholar is included among the top collaborators of Zhihuang Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhihuang Hu. Zhihuang Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xin, Wenyue Yang, Zhen Wang, et al.. (2024). Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma. Frontiers in Immunology. 15. 1421604–1421604. 1 indexed citations
2.
Lin, Ying, Bo Yu, Hongyu Zhang, et al.. (2023). Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. Journal of Cancer Research and Clinical Oncology. 149(11). 8663–8671. 20 indexed citations
3.
Lai, Hongyan, Chang Liu, Xin Zhang, et al.. (2023). Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer. Cancer Science. 114(7). 2774–2786. 6 indexed citations
4.
Zhao, Xinmin, Xianghua Wu, Hui Yu, et al.. (2022). Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. Frontiers in Immunology. 13. 1003581–1003581. 4 indexed citations
5.
Chen, Maojian, Yajun Li, Ning Li, et al.. (2021). Practices and Hindrances in Cancer Pain Management: Results of a National Multi-Cancer Center Survey Among Healthcare Professionals in China. Cancer Management and Research. Volume 13. 1709–1717. 2 indexed citations
6.
Wu, Meng‐Fang, Zhihuang Hu, Yanling Zhang, et al.. (2020). Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. Signal Transduction and Targeted Therapy. 5(1). 117–117. 42 indexed citations
7.
Sun, Si, Zhihuang Hu, Shenglin Huang, et al.. (2019). REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression. Journal of Cancer Research and Clinical Oncology. 145(9). 2273–2283. 8 indexed citations
8.
9.
Cai, Junchao, Lishan Fang, Yongbo Huang, et al.. (2017). Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nature Communications. 8(1). 15870–15870. 148 indexed citations
10.
Hu, Zhihuang, Wenhua Liang, Yunpeng Yang, et al.. (2016). Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting. Medicine. 95(2). e2476–e2476. 18 indexed citations
11.
Zhou, Ting, Lie Zheng, Zhihuang Hu, et al.. (2015). The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment. Scientific Reports. 5(1). 7683–7683. 9 indexed citations
12.
Fang, Wenfeng, Tao Qin, Yunpeng Yang, et al.. (2015). Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Medical Oncology. 32(3). 86–86. 104 indexed citations
13.
He, Xiaobo, Ting Zhou, Yunpeng Yang, et al.. (2015). Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. Clinical Lung Cancer. 16(6). e165–e171. 74 indexed citations
14.
Ma, Yuxiang, Yunpeng Yang, Yan Huang, et al.. (2014). An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System. Lung Cancer. 84(3). 301–306. 10 indexed citations
15.
Zhang, Li, Yan Huang, Tao Qin, et al.. (2014). Multicenter, randomized, controlled, open-label study of bevacizumab combined with carboplatin and paclitaxel versus carboplatin and paclitaxel in patients with metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology. 32(15_suppl). TPS6100–TPS6100. 2 indexed citations
16.
Hong, Shaodong, Ting Zhou, Wenfeng Fang, et al.. (2014). The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. Tumor Biology. 36(5). 3389–3397. 104 indexed citations
17.
Hong, Shaodong, Wenfeng Fang, Zhihuang Hu, et al.. (2014). A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population. Scientific Reports. 4(1). 7268–7268. 25 indexed citations
18.
19.
Fang, Wenfeng, Wenhua Liang, Yan Huang, et al.. (2013). Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.. PubMed. 5(5). 585–92. 28 indexed citations
20.
Zhang, Jianwei, et al.. (2012). Retrospective analysis of the correlation between hepatitis B Virus infection and chemotherapy-induced hepatic injury in patients with lung cancer. Clinical Oncology and Cancer Research. 39(8). 465–468. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Syrigos Breakdown of academic impact, for papers by Pascal Wolter Breakdown of academic impact, for papers by Alain Gelibter Breakdown of academic impact, for papers by Óscar Juan Breakdown of academic impact, for papers by Fumihiko Hirai Breakdown of academic impact, for papers by Lara Pijuán Breakdown of academic impact, for papers by Morena Fasano Breakdown of academic impact, for papers by Jesús García-Donás Breakdown of academic impact, for papers by Nobuyuki Mizunuma Breakdown of academic impact, for papers by Mireia Margelí Vila
Rankless by CCL
2026